Supplementary Figure 1 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1. Lapatinib clinical trial scheme
Authors: Mario Giuliano, Huizhong Hu, Yen-Chao Wang, Xiaoyong Fu, Agostina Nardone, Sabrina Herrera, Sufeng Mao, Alejandro Contreras, Carolina Gutierrez, Tao Wang, Susan G. Hilsenbeck, Carmine De Angelis, Nicholas J. Wang, Laura M. Heiser, Joe W. Gray, Sara Lopez-Tarruella, Anne C. Pavlick, Meghana V. Trivedi, Gary C. Chamness, Jenny C. Chang, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361884261
